Duloxetine in adults with ADHD: a randomized, placebo-controlled pilot study

Journal of Attention Disorders
Mathieu BilodeauSmadar Valérie Tourjman

Abstract

To assess the effect of duloxetine on ADHD in adults. In a 6-week double-blind trial, 30 adults with ADHD received placebo or duloxetine 60 mg daily. The Conners' Adult ADHD Rating Scale (CAARS) and the Clinical Global Impression Scales (CGI) were used to assess symptom severity and clinical improvement. The Hamilton Anxiety Rating Scale (HARS) and the Hamilton Depression Rating Scale (HDRS) were used to measure the effect on anxiety and depressive symptoms. The Duloxetine group showed lower score on CGI-Severity at Week 6 (3.00 vs. 4.07 for placebo, p < .001), greater improvement on CGI-Improvement (2.89 vs. 4.00 at Week 6, p < .001), and greater decreases on five of eight subscales of the CAARS. There was no treatment group effect on HDRS or HARS scores. Duloxetine may be a therapeutic option for adults with ADHD, but further studies are required to replicate these findings in larger samples.

References

Dec 14, 2002·CNS Drug Reviews·Kelly D KarpaJoan M Lakoski
Jan 1, 1959·The British Journal of Medical Psychology·M HAMILTON
Feb 1, 1960·Journal of Neurology, Neurosurgery, and Psychiatry·M HAMILTON
Sep 30, 2003·Journal of Psychopharmacology·Ian D Maidment
Feb 9, 2007·Expert Review of Neurotherapeutics·Mohammad Reza Mohammadi, Shahin Akhondzadeh
Jul 12, 2007·International Journal of Methods in Psychiatric Research·Ronald C KesslerDavid L Van Brunt
Oct 6, 2007·International Clinical Psychopharmacology·Richard C SheltonMichael J Detke
Apr 11, 2009·Journal of Attention Disorders·Smadar Valérie Tourjman, Mathieu Bilodeau
Jul 8, 2009·The International Journal of Neuropsychopharmacology·Agnes MészárosIstván Bitter
Oct 6, 2009·European Psychiatry : the Journal of the Association of European Psychiatrists·H Niederhofer
Apr 20, 2010·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Stephen BruntonMichael J Robinson
Dec 31, 2010·Journal of Clinical Psychopharmacology·Daniel M Campagne
Apr 2, 2011·Human Psychopharmacology·Javad Mahmoudi-GharaeiToktam Faghihi
May 7, 2011·Expert Opinion on Drug Safety·Istvan BitterPal Czobor

❮ Previous
Next ❯

Citations

Dec 24, 2015·Expert Review of Neurotherapeutics·Massimiliano BuoliWiepke Cahn
Feb 17, 2015·Neurochemistry International·Emili Banerjee, Krishnadas Nandagopal
Nov 21, 2017·Current Psychiatry Reports·Frederick W ReimherrTammy A Steans
Sep 18, 2020·Expert Opinion on Emerging Drugs·Marco PozziMaria Nobile
Nov 22, 2019·Frontiers in Psychiatry·Maria Rosaria Anna MuscatelloAntonio Bruno

❮ Previous
Next ❯

Methods Mentioned

BETA
pregnancy test

Clinical Trials Mentioned

NCT00940693

Related Concepts

Related Feeds

Attention Disorders

Attention is involved in all cognitive activities, and attention disorders are reported in patients with various neurological diseases. Here are the latest discoveries pertaining to attention disorders.

Related Papers

Pain Medicine : the Official Journal of the American Academy of Pain Medicine
Vladimir SkljarevskiMiroslav Backonja
BJOG : an International Journal of Obstetrics and Gynaecology
Philip van KerrebroeckDuloxetine Urinary Incontinence Study Group
© 2021 Meta ULC. All rights reserved